Compounds within the patent application are agonists of HsClpP that possess interesting in vitro activities against a variety of human derived cancer cell lines.
Publication of PCT patent application describing new HsClpP agonists by CEAMED SA (WO 2025/008381)
Comments
One response to “Publication of PCT patent application describing new HsClpP agonists by CEAMED SA (WO 2025/008381)”
-
Hola, esto es un comentario.
Para empezar a moderar, editar y borrar comentarios, por favor, visita en el escritorio la pantalla de comentarios.
Los avatares de los comentaristas provienen de Gravatar.
Leave a Reply to Un comentarista de WordPress Cancel reply